These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21399893)

  • 21. Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer.
    Kim SK; Jung WH; Koo JS
    Int J Clin Exp Pathol; 2014; 7(6):3224-34. PubMed ID: 25031743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
    Ko E; Park SE; Cho EY; Kim Y; Hwang JA; Lee YS; Nam SJ; Bang S; Park J; Kim DH
    Breast Cancer Res; 2010; 12(6):R100. PubMed ID: 21092257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD; Nassar A; Siddiqui MT; Cohen C
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors.
    Nagai MA; Da Rós N; Neto MM; de Faria Junior SR; Brentani MM; Hirata R; Neves EJ
    Int J Cancer; 2004 Oct; 111(6):892-9. PubMed ID: 15300801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
    Fournier A; Fabre A; Mesrine S; Boutron-Ruault MC; Berrino F; Clavel-Chapelon F
    J Clin Oncol; 2008 Mar; 26(8):1260-8. PubMed ID: 18323549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.
    Wiebe JP; Zhang G; Welch I; Cadieux-Pitre HA
    Breast Cancer Res; 2013 May; 15(3):R38. PubMed ID: 25927181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
    Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2 expression in Brazilian patients with estrogen and progesterone receptor-negative breast carcinoma.
    Ramalho S; Serra KP; Vassallo J; Soares FA; Pinto GA; Teixeira LC; da Cunha IW; Derchain SF; de Souza G
    Acta Histochem; 2013 Mar; 115(2):120-7. PubMed ID: 22647460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas.
    Lal P; Tan LK; Chen B
    Am J Clin Pathol; 2005 Apr; 123(4):541-6. PubMed ID: 15743737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of ER, PR and HER-2 receptor expression in breast cancer patients presenting to a semi urban cancer centre in Western India.
    Singh R; Gupta S; Pawar SB; Pawar RS; Gandham SV; Prabhudesai S
    J Cancer Res Ther; 2014; 10(1):26-8. PubMed ID: 24762482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.
    Osborne JR; Port E; Gonen M; Doane A; Yeung H; Gerald W; Cook JB; Larson S
    J Nucl Med; 2010 Apr; 51(4):543-50. PubMed ID: 20237034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
    Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
    Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
    Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.
    Yau C; Benz CC
    Breast Cancer Res; 2008; 10(4):R61. PubMed ID: 18631401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
    Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
    Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
    Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
    Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen receptor and progesterone receptor expression in normal terminal duct lobular units surrounding invasive breast cancer.
    Yang XR; Figueroa JD; Hewitt SM; Falk RT; Pfeiffer RM; Lissowska J; Peplonska B; Brinton LA; Garcia-Closas M; Sherman ME
    Breast Cancer Res Treat; 2013 Feb; 137(3):837-47. PubMed ID: 23271326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.